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Background: Thailand has experienced a longstanding epidemic of HIV among people who inject drugs (PWID).
However, antiretroviral treatment (ART) coverage among HIV-positive PWID has historically remained low. While
ongoing drug law enforcement involving periodic police crackdowns is known to increase the risk of HIV transmission
among Thai PWID, the impact of such drug policy approaches on the ART uptake has been understudied. Therefore,
we sought to identify factors associated with not receiving ART among HIV-positive PWID in Bangkok, Thailand, with a
focus on factors pertaining to drug law enforcement.
Methods: Data were collected from a community-recruited sample of HIV-positive PWID in Bangkok who participated
in the Mitsampan Community Research Project between June 2009 and October 2011. We identified factors associated
with not receiving ART at the time of interview using multivariate logistic regression.
Results: In total, 128 HIV-positive PWID participated in this study, with 58 (45.3%) reporting not receiving ART at the
time of interview. In multivariate analyses, completing less than secondary education (adjusted odds ratio [AOR]: 3.32 ;
95% confidence interval [CI]: 1.48 – 7.45), daily midazolam injection (AOR: 3.22, 95% CI: 1.45 – 7.15) and exposure to
compulsory drug detention (AOR: 3.36, 95% CI: 1.01 – 11.21) were independently and positively associated with not
receiving ART. Accessing peer-based healthcare information or support services was independently and
positively associated with receiving ART (AOR: 0.21, 95% CI: 0.05 – 0.84).
Conclusions: Approximately half of our study group of HIV-positive PWID reported not receiving ART at the
time of interview. Daily midazolam injectors, those with lower education attainment, and individuals who had
been in compulsory drug detention were more likely to be non-recipients of ART whereas those who accessed
peer-based healthcare-related services were more likely to receive ART. These findings suggest a potentially adverse
impact of compulsory drug detention and highlight the need to expand interventions to facilitate access to ART
among HIV-positive PWID in this setting.
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In many parts of the world, people who inject drugs
(PWID) are severely affected by HIV/AIDS [1]. It is esti-
mated that injection drug use accounts for more than
one-quarter of new HIV infections outside of sub-Saharan
Africa [2]. Injection drug use-driven HIV epidemics are
particularly salient in Asia, which accommodates seven of
the 15 countries worldwide where >100,000 PWID reside
and where an estimated HIV prevalence among PWID
is >10% [3]. Although antiretroviral treatment (ART) has
dramatically reduced HIV-related morbidity and mortal-
ity [4,5], and has recently been shown to prevent HIV
transmission [6], access to ART is disproportionately
low among PWID in many settings [7].
Recent reviews have suggested various factors constrain-
ing access to ART among PWID worldwide, including in-
dividual (e.g., ongoing drug use), social (e.g., stigma), and
structural factors (e.g., incarceration) [8,9]. In particular,
barriers stemming from punitive drug policies have drawn
increasing attention [8,9]. Although recent international
research has elucidated the adverse effects of incarceration
on access and adherence to ART [8,10], other impacts as-
sociated with the criminalization of drug use have not
been fully investigated. In particular, some Asian coun-
tries, including Thailand, continue to operate systems of
compulsory drug detention [11-13], despite twelve United
Nations agencies calling on governments to abolish such
systems due to the associated human rights violations and
substandard addiction treatment [14]. In Thailand, the
number of people who use drugs detained amounted to
more than 102,000 in 2011 [15].
Thailand has experienced a longstanding HIV epidemic
among PWID, with an estimated HIV prevalence in this
population ranging between 30–50% for more than two
decades [16,17]. Since 2000, Thailand has developed a na-
tional initiative to provide ART for free or at a reduced
cost [18]. As a result, in 2011, 65% of eligible people living
with HIV (PLHIV) reportedly received ART, which stands
as a relatively high level of coverage for a middle-income
country [17,19]. In contrast, only 2 per 100 HIV-positive
PWID were estimated to have ever accessed ART in
Thailand in 2007 [7], although in our 2009 study, 45% of
67 HIV-positive PWID in Bangkok reported receiving
ART at the time of interview [20].
The Thai government has for many years implemented
drug prohibition approaches involving periodic police
crackdowns [21]. While some potentially effective measures
to improve access to ART among HIV-positive PWID exist
in this setting, including methadone treatment and peer-
support groups [8], few studies have investigated factors
that promote or undermine uptake of ART among PWID
within a context of drug law enforcement involving peri-
odic police crackdowns. Therefore, we sought to iden-
tify factors associated with not receiving ART amonga community-recruited sample of HIV-positive PWID in




Data were derived from the Mitsampan Community
Research Project, a collaborative research effort involving
the Mitsampan Harm Reduction Center (MSHRC; a drug
user-run drop-in centre in Bangkok, Thailand), Thai AIDS
Treatment Action Group (Bangkok, Thailand), Chulalongkorn
University (Bangkok, Thailand), and the British Columbia
Centre for Excellence in HIV/AIDS/University of British
Columbia (Vancouver, Canada). This serial cross-sectional
study aims to investigate drug-using behaviour, healthcare
access, and other drug-related harms among PWID in
Bangkok. Between June 2009 and October 2011, the
research partners undertook two waves of surveying,
which involved an accumulated total of 757 community-
recruited PWID in Bangkok. Potential participants were
recruited through peer outreach efforts and word-of-
mouth, and were invited to attend the MSHRC or O-Zone
House (another drop-in centre in Bangkok) in order to
be part of the study. Recruitment criteria included adults
residing in Bangkok or in adjacent provinces who had
injected drug(s) in the past six months. All participants pro-
vided informed consent and completed an interviewer-
administered questionnaire eliciting a range of information,
including demographic characteristics, drug use patterns,
HIV serostatus, and experiences with drug law enforce-
ment and accessing healthcare. Upon completion of the
questionnaire, participants received a stipend of 350 Thai
Baht (approximately US$12). The study was approved by
the research ethics boards at Chulalongkorn University
(COA No. 085/2009, 093/2011) and the University of British
Columbia (H08-00702, H11-00581).
All participants who completed the interview in 2009
or 2011 and reported being HIV-positive were eligible
for inclusion in this study. Given that some individuals
were interviewed in both 2009 and 2011, we included all
participants from the first wave and only new participants
from the second wave in order to ensure the independence
of the observations analyzed in this study. The sample of
each survey wave was further restricted to individuals who
had complete data for the present analyses.
Variable selection
The primary outcome of interest was not receiving ART
at the time of interview, defined as answering “No” to
the following question: “Are you currently taking antire-
trovirals (ARVs)?” Based on previous literature [8], a set
of explanatory variables were hypothesized to be associ-
ated with the outcome. Demographic characteristics in-
cluded median age (≥38 years vs. < 38 years); gender
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education vs. ≥ secondary education). Indicators for the
severity of substance use included: heroin injection (daily
vs. < daily); methamphetamine injection (daily vs. < daily);
midazolam (a short-acting benzodiazepine) injection (daily
vs. < daily); and alcohol consumption (daily vs. < daily).
Exposure to drug law enforcement included: ever beaten
by police; ever incarcerated; and ever in compulsory drug
detention. Finally, experiences with accessing healthcare
included: ever accessed methadone treatment; ever received
healthcare information or support services at the MSHRC;
and reporting barriers to healthcare (any vs. none). As in
our previous work [22], our barriers to healthcare variable
included a range of potential barriers, including but not
limited to: long wait times, poor treatment by healthcare
providers, financial barriers, and transportation issues. All
variables were coded dichotomously as yes vs. no, unless
otherwise stated. Variables related to drug use referred to
the previous six months.Figure 1 Determination of the analytic sample.Statistical analyses
To examine bivariate associations between the outcome
and the explanatory variables of interest, we used the
Pearson X2 test. Fisher’s exact test was used when one or
more of the cells contained expected values less than or
equal to five. Three variables (i.e., methamphetamine in-
jection, alcohol consumption, and ever incarcerated) met
this criterion. Next, we used an a priori-defined statistical
protocol that examined factors associated with the out-
come by fitting a multivariate logistic regression model
that included all variables that were significantly associ-
ated with the outcome at the p < 0.05 level in bivariate
analyses. All p-values were two-sided. All statistical
analyses were performed using SAS software version
9.3 (SAS, Cary, NC).
Results
Figure 1 describes the determination of the analytic sam-
ple. As shown, 133 (20.5%) of 650 unique individuals who
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in 2009 and 2011 identified themselves as being HIV-
positive. Among the remaining 517 participants who did
not report being HIV-positive, 336 (65.0%) reported
having been tested for HIV in the previous six months. Of
the 133 HIV-positive participants, 5 (3.8%) were excluded
from the present analysis due to incomplete data. There-
fore, a total of 128 HIV-positive participants were eligible
for the present study.
Among 128 HIV-positive PWID participated in this
study, 25 (19.5%) were women, and the median age was
38 years (interquartile range: 34 – 44 years). In total, 58
(45.3%) individuals reported not receiving ART at the
time of interview. Of these, 36 (62.1%) reported having
not seen an HIV doctor on a regular basis (i.e., at least
once in six months).
Table 1 shows the summary statistics of the sample and
the results of bivariate analyses. As shown, in bivariate ana-
lyses, completing less than secondary education (odds ratio
[OR]: 3.54; 95% confidence interval [CI]: 1.70 – 7.39), daily
midazolam injection in the previous six months (OR: 3.64;
95% CI: 1.75 – 7.58) and having ever been in compulsory
drug detention (OR: 3.08; 95% CI: 1.09 – 8.72) were signifi-
cantly and positively associated with not receiving ART.
Having ever received healthcare information or support
services at the MSHRC was significantly and negatively as-
sociated with not receiving ART (OR: 0.22; 95% CI: 0.06 –
0.80).
Table 2 shows the results of the multivariate analysis.
As shown, completing less than secondary education
(adjusted odds ratio [AOR]: 3.32; 95% CI: 1.48 – 7.45),
daily midazolam injection (AOR: 3.22; 95% CI: 1.45 –
7.15) and having ever been in compulsory drug detention
(AOR: 3.36; 95% CI: 1.01 – 11.21) remained independently
and positively associated with not receiving ART. Having
ever received healthcare information or support services
at the MSHRC also remained independently and nega-
tively associated with the outcome (AOR: 0.21; 95% CI:
0.05 – 0.84).
Discussion
We found that approximately half of our study group of
HIV-positive PWID in Bangkok reported not receiving
ART. Because blood specimens were not collected, we
were unable to assess the indication for ART initiation
(e.g., CD4 counts <350 cells/mm3 according to the 2010
Thai national guidelines for ART [19]) among those not
receiving ART at the time of interview. However, the
majority of Thai PLHIV have been shown to be diag-
nosed with HIV infection at a late stage of HIV disease,
with approximately 60% starting ART with CD4 levels
of <100 cells per cubic millimeter [17], and therefore a
substantial portion of our sample of untreated HIV-positive
PWID may have met ART eligibility criteria. Futureresearch should investigate stages of HIV disease among
HIV-positive PWID who are not receiving ART. Nonethe-
less, given the persistently high prevalence of syringe shar-
ing among HIV-positive PWID in this setting [17,20,23],
and the now widely recognized impact of HIV treatment
on the prevention of new HIV infections [24], ensuring ac-
cess to ARTamong PWID remains a high priority in Thai-
land’s response to the HIV epidemic [17]. In this regard,
our findings provide important insights into barriers to
and facilitators of ART access among HIV-positive PWID
in Bangkok. In addition, we note that evolving ART guide-
lines have dramatically increased the proportion of PLHIV
in need of ART, particularly among high-risk populations
marked with significant comorbidities, including PWID,
as the Joint United Nations Programme on HIV/AIDS has
recently estimated that approximately 85% of PLHIV are
eligible for ART provision under the 2013 World Health
Organization criteria [25]. Furthermore, beginning in
October 2014, the Thai national ART guidelines has re-
moved CD4 count from the ART eligibility criteria, and
now all PLHIV in Thailand are eligible for ART initiation
regardless of CD4 count [23].
Of particular concern is the independent association
between exposure to compulsory drug detention and not
receiving ART. In Thailand, it has been reported that
some public hospitals collect and share information
about individual drug use with police [26]. Given the pu-
nitive nature of compulsory drug detention centres [21],
our findings may suggest that HIV-positive PWID who
have been detained in such centres are reluctant to ac-
cess HIV treatment due to fear of disclosing their drug
use to healthcare providers and thereby risk being re-
admitted to detention centres. Consistent with our inter-
pretation, a recent study also found an independent
relationship between exposure to compulsory drug de-
tention and the avoidance of healthcare among PWID in
this setting [21]. Furthermore, a previous report also
suggested inconsistent availability of ART across the cus-
todial settings as well as a lack of continuity of health-
care, including ART, on entry to and on release from
detention in Thailand [26]. These findings suggest that
compulsory drug detention may be placing an undue
burden on public health by undermining ex-detainees’
access to HIV treatment. Future research should longitu-
dinally assess the impact of compulsory drug detention
exposure on HIV disease progression in this setting.
The finding that HIV-positive PWID who accessed
peer-based healthcare information and support services
were more likely to be on ART is congruent with a large
body of literature indicating the effectiveness of peer-
based interventions in providing HIV/AIDS education
and supporting access to HIV care among PWID [8,27].
Our findings that the positive effect of peer-based sup-
port services on the ART uptake remained significant
Table 1 Bivariate associations with not receiving ART among HIV-positive PWID in Bangkok, Thailand (n = 128)
Characteristic Currently on ART Odds ratio (95%CI) p - value
No 58 (45.3%) Yes 70 (54.7%)
Demographic
Older age
≥38 years old 30 (51.7%) 35 (50.0%) 1.07 (0.53 – 2.15) 0.846
<38 years old 28 (48.3%) 35 (50.0%)
Gender
Female 12 (20.7%) 13 (18.6%) 1.14 (0.48 – 2.75) 0.764
Male 46 (79.3%) 57 (81.4%)
Education attainment
< Secondary education 34 (58.6%) 20 (28.6%) 3.54 (1.70 – 7.39) <0.001
≥ Secondary education 24 (41.4%) 50 (71.4%)
Substance use behaviour
Heroin injection*
Daily 9 (15.5%) 8 (11.4%) 1.42 (0.51 – 3.96) 0.497
< Daily 49 (84.5%) 62 (88.6%)
Methamphetamine injection*
Daily 7 (12.1%) 3 ( 4.3%) 3.07 (0.65 – 19.10) 0.184†
< Daily 51 (87.9%) 67 (95.7%)
Midazolam injection*
Daily 38 (65.5%) 24 (34.3%) 3.64 (1.75 – 7.58) <0.001
< Daily 20 (34.5%) 46 (65.7%)
Alcohol consumption*
Daily 3 ( 5.3%) 3 ( 4.3%) 1.24 (0.16 – 9.63) >0.999†
< Daily 54 (94.7%) 67 (95.7%)
Experiences with drug law enforcement
Ever beaten by police
Yes 33 (56.9%) 28 (40.0%) 1.98 (0.98 – 4.01) 0.057
No 25 (43.1%) 42 (60.0%)
Ever incarcerated
Yes 56 (96.6%) 63 (90.0%) 3.11 (0.56 – 31.65) 0.182†
No 2 ( 3.4%) 7 (10.0%)
Ever in compulsory drug detention
Yes 13 (22.4%) 6 ( 8.6%) 3.08 (1.09 – 8.72) 0.028
No 45 (77.6%) 64 (91.4%)
Healthcare access
Ever accessed methadone treatment
Yes 51 (87.9%) 62 (88.6%) 0.94 (0.32 – 2.77) 0.911
No 7 (12.1%) 8 (11.4%)
Ever received healthcare information or support services at the MSHRC
Yes 3 ( 5.2%) 14 (20.0%) 0.22 (0.06 – 0.80) 0.014
No 55 (94.8%) 56 (80.0%)
Reporting barriers to healthcare*
Any 33 (56.9%) 48 (68.6%) 0.61 (0.29 – 1.25) 0.173
None 25 (43.1%) 22 (31.4%)
PWID: people who inject drugs; ART: antiretroviral treatment; CI: confidence interval; MSHRC: Mitsampan Harm Reduction Center.
*denotes activities in the previous 6 months.
†Fisher’s exact test was used.
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Table 2 Multivariate logistic regression analysis of factors associated with not receiving ART among HIV-positive PWID
in Bangkok, Thailand (n = 128)
Characteristic Adjusted odds ratio (95% CI) p-value
Education attainment
(< Secondary education vs. ≥ Secondary education) 3.32 (1.48 – 7.45) 0.004
Midazolam injection*
(Daily vs. < Daily) 3.22 (1.45 – 7.15) 0.004
Ever in compulsory drug detention
(Yes vs. No) 3.36 (1.01 – 11.21) 0.049
Ever received healthcare information or support services at the MSHRC
(Yes vs. No) 0.21 (0.05 – 0.84) 0.028
PWID: people who inject drugs; ART: antiretroviral treatment; CI: confidence interval; MSHRC: Mitsampan Harm Reduction Center.
*denotes activities in the previous 6 months.
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further suggest the effectiveness of such peer-based inter-
ventions. Since 1992, the Thai Ministry of Public Health
has supported many PLHIV peer support groups, which
have been working to facilitate access to HIV treatment
among PLHIV in the country [28]. However, until re-
cently, there have been few PWID-specific PLHIV peer
support services, and those that exist are primarily funded
by international donors [29]. The MSHRC is one of those
few sites that provide a variety of services via a peer-
delivered approach, including sterile syringe distribution,
harm reduction education, food and drinks, and support
for healthcare access [30]. A previous study has shown
that this model has successfully reached sub-populations
of PWID who were particularly vulnerable to HIV infec-
tion and other drug-related harm in this setting [30]. Given
the profound stigma against PWID in healthcare settings
in Thailand [26,31], the expansion of PWID-specific peer
support, such as that offered at the MSHRC, may be cru-
cial for facilitating access to ART among HIV-positive
PWID in this setting.
We also found that daily midazolam injection was inde-
pendently associated with not receiving ART. Midazolam is
a short-acting benzodiazepine that can be legally obtained
through private clinics in Bangkok [32]. While injection of
benzodiazepines is common among opioid users in many
settings [33,34], in Bangkok, midazolam is the most com-
monly injected drug among PWID [22]. Amnesia and severe
injection-related injuries and disease associated with mid-
azolam use [22] indicate a need for additional support ser-
vices if these daily midazolam injectors are to initiate ART.
This study has several limitations. First, we cannot
infer causation from this observational study. Further,
the cross-sectional study design did not allow us to as-
sess temporal relationships between the outcome and
explanatory variables. Second, due to the lack of HIV-
related clinical data (e.g., CD4 counts), we were unable
to assess the eligibility for ART among our sample. While
we also recognize that it would have been ideal to utilize amore sensitive assessment of untreated HIV infection
(e.g., whether a participant was not receiving ART at the
time of interview due to poor adherence, treatment discon-
tinuation, or being ineligible for ART, etc.), we were unable
to include such measurements in our questionnaire. Future
research should seek to use a refined measure of untreated
HIV infection. To this end, an exploratory qualitative study
to understand reasons for not accessing ART would pro-
vide useful data for refining the measure and selecting the
study variables. Third, the self-reported data may have
been affected by some reporting biases, including socially
desirable responding and recall bias. For example, these
biases might have led to the underestimation of the preva-
lence of compulsory drug detention exposure (due to so-
cially desirable reporting) and ever receiving services at the
MSHRC (due to recall bias). However, we believe that it is
unlikely that such information biases differentially influ-
enced the data by HIV treatment status. We also note that
this type of self-reported data has been commonly utilized
in observational studies involving PWID and has been
found to be valid [35]. Lastly, due to the small sample size,
there were wide intervals around some of the estimates re-
ported. Also, as the study sample was not randomly se-
lected, our findings may not be generalizable to PWID
populations in Thailand or elsewhere.
Conclusions
In summary, we found that about half of our study group
of HIV-positive PWID in Bangkok reported that they were
not receiving ART at the time of interview. Daily midazo-
lam injectors, those with lower education attainment, and
individuals who had been in compulsory drug detention
were more likely to be non-recipients of ART. In contrast,
individuals who accessed peer-based healthcare information
and support services were more likely to be on ART. These
findings suggest a potentially adverse impact of compulsory
drug detention and indicate a need for expanding interven-
tions to facilitate access to ART among HIV-positive PWID
in this setting.
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